Research & Reviews: Journal of Pharmacology and Toxicological Studies
e-ISSN: 2322-0139
p-ISSN: 2322-0120

Topical Dosage Forms of different Drugs by FDA: A Bioequivalence Study

Satya Varali*
Department of Human Genetics, Visakhapatnam, Andhra Pradesh, India

Review Article

Received: 26/08/2016
Revised: 30/08/2016
Accepted: 03/09/2016

*For Correspondence

Satya Varali, Department of Human Genetics, Andhra University, Visakhapatnam, Andhra Pradesh, India
E-mail: msvarali@gmail.com

Keywords: Bioequivalence, Topical dosage, Drug, Therapeutic dose

ABSTRACT

The absorption rate of the test drug doesn't demonstrate a huge difference from the rate of absorption of the reference drug when administered at the same therapeutic dose of the active ingredient under comparable test conditions. The Pharmaceutical Development section gives a chance to present the information from the application of scientific approaches and risk management and from manufacturing process. First it as created for the original marketing application and second updated to support new information gained over the product lifecycle. The Pharmaceutical Development section is intended to provide a more extensive comprehension of the product and manufacturing process for analysts.

INTRODUCTION

Skin being the biggest organ of the human body and in light of the fact that it offers particular favorable circumstances over different courses [1-5], for example, simple entry and bypassing the main pass digestive system, it introduces a gigantic open door for controlling medications [6,7]. Measurement frames intended to convey drugs through the skin can be comprehensively characterized into topical and transdermal dose shapes [8-10]. Topical measurement structures, for example, gels, creams, salves, moisturizers are intended to be connected with skin for confined conveyance of medications to the influenced regions [11]. They contrast from transdermal measurement structures, for example, patches, in the way that the medications connected topically are more averse to be ingested into the systemic flow [12-18]. Their site of activity is either in one of the skin layers or in more profound tissues under the skin. The distinctions in piece and technique for creation can be key viewpoints which manage the site of conveyance of medication from these dose shapes [19-25]. The blood supply, however, being available in the dermal layer of skin, can prompt some retention of medications to the systemic dissemination even from topical dose shapes.

Assembling and offer of any medication item is administered by government laws of direction [26]. The trailblazer organization gets the sole rights and consent to make and offer another medication item for a specific timeframe. Once that patent for the medication item lapses, any organization other than the trailblazer organization can make and offer that medication item [27 -30]. For any dose shape be that as it may, a nonexclusive organization needs to submit bioequivalence information keeping in mind the end goal to show equivalency to the pioneer item [31].

A medication should be considered bioequivalent to a recorded medication if the rate and degree of ingestion of the medication don't demonstrate any critical distinction from the rate and degree of retention of the recorded medication when directed at the same molar measurements of the remedial fixing under comparable exploratory conditions in a solitary dosage or different dosages [30].

e-ISSN: 2322-0139
p-ISSN: 2322-0120

For dose frames which demonstrate their viability by getting retained into the systemic course, (for example, patches), blood levels of medication are a decent measure of rate and degree of retention of medication as it properly mirrors the measure of medication at its site of activity [32-35]. For topical measurements frames, be that as it may, the blood levels won't not be even discernible or the medication may have different courses, making blood levels not illustrative of the measure of medication present at the site of activity [36,37].

For a medication that is not planned to be consumed into the circulation system, the secretary may set up option, logically substantial strategies to demonstrate bioequivalence, if the option techniques are relied upon to distinguish a noteworthy contrast between the medication and the recorded medication in security and helpful impact [33].

Pharmacokinetic Technique

As specified before, blood levels are not a satisfactory measure of the medication present at the site of activity for topical dose shapes [38]. There is only one particular situation where the office acknowledges pharmacokinetic information to indicate bioequivalence. Lidocaine patches 5% are intended to be connected on skin for neighborhood anesthesia. For this situation, adequate medication achieves the blood flow to be identified and tranquilize level in plasma is relative to the measure of medication at the site of activity (nerves in dermal tissue) [39,40]. Pharmacokinetic information can in this way be submitted while indicating bioequivalence for Lidocaine patches 5% [41].

In–vitro Release Method

This technique is like *in-vitro* penetration, however, utilizes a manufactured layer rather than skin to survey the arrival of medication from plans without joining hindrance properties of skin [42-45]. This technique does not go about as surrogate for clinical concentrates but rather can be utilized as a valuable test to evaluate item equivalence under certain scale up and post endorsement changes (SUPAC). There is another section (part no 1724) which has as of late been included year 2013 to the USP 36-NF 31, enumerating the *in-vitro* discharge strategy and its application [46-50].

In-vitro Permeation Method

The technique includes testing pervasion of medication crosswise over extracted human/creature skin utilizing device like Franz cells [51]. Great in vitro and in-vivo relationship information has been appeared by two or three analysts utilizing this strategy [52]. The organization, however, does not acknowledge it as a surrogate for bioequivalence. The constraints to this model incorporate the absence of live tissue, hidden steady structure, metabolic movement and systemic course [53-56].

Skin Blanching Method

It is a pharmacodynamic technique, which is acknowledged by the FDA to show equivalency of topical dose shapes containing glucocorticoids [57]. The site of activity of glucocorticoids is the glucocorticoid receptors in the suitable epidermis and dermis. The pharmacodynamic reaction which is measured is the narrowing of microvasculature of skin, which causes skin whitening (brightening) at the site of activity [58,59].

Topical Compounds

A biowaiver might be allowed for such items if the nonexclusive item contains same dynamic fixing in the same focus as the trailblazer item and has no inert fixing, (for example, penetration enhancer) or other change which influences bioavailability [60-63].

Acyclovir Medicine/Ointment

A biowaiver might be allowed for such items if the nonexclusive item contains same dynamic fixing in the same focus as the trailblazer item and has no inert fixing, (for example, penetration enhancer) or other change which influences bioavailability [64-70].

CONCLUSION

Bioequivalence for topical dose structures is right now restricted to clinical viability trials where the result is dichotomous in nature as "Yes" or "No" [71-78]. This outcomes in low factual essentialness of these trials and require a few many subjects to be selected. Considering this, FDA additionally recognizes the need to create surrogate techniques to demonstrate bioequivalence of topical medication items. This is, however, testing given the quantity of locales of activity for various topical items and only a small amount of measurements (by and large under 1%) being getting retained through skin [79-83]. Strategy enhancement took after by acceptance and confirmation at numerous research centers or more all dedication from commercial ventures and office to give foundation and assets is the need of hour [84-90].

REFERENCES

1. Zhu W, et al. In-vitro Release of Rapamycin from a Thermosensitive Polymer for the Inhibition of Vascular Smooth Muscle Cell Proliferation. J Bioequiv Availab. 2009;1:003-012.
2. Anderson C, et al. Ethanol absorption across human skin measured by in vivo microdialysis technique. Acta Derm Venereol. 1991;71:389-393.
3. Benfeldt E, et al. Bioequivalence of topical formulations in humans:evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol. 2007;127:170–178.
4. Shakeel F, et al. Comparative Pharmacokinetic Profile of Aceclofenac from Oral and Transdermal Application. J Bioequiv Availab. 2009;1:013-017.
5. Ahmed T, et al. Bioavailability and Interaction Potential of Atorvastatin and Losartan on Co-administration in Healthy Human Subjects. J Bioequiv Availab. 2009;1:018-027.
6. Benfeldt E and Serup J. Effect of barrier perturbation on cutaneous penetration of salicylic acid in hairless rats:in vivo pharmacokinetics using microdialysis and non-invasive quantifi cation of barrier function. Arch Dermatol Res. 1999;291:517–526.
7. Setiawati E, et al. Bioequivalence Study with Two Naproxen Sodium Tablet Formulations in Healthy Subjects. J Bioequiv Availab. 2009;1:028-033.
8. Hawthorne KM, et al. Biotechnologically-modified Carrots:Calcium Absorption Relative to Milk. J Bioequiv Availab. 2009;1:034-038.
9. Shakeel F, et al. Solubility and Dissolution Improvement of Aceclofenac using Different Nanocarriers. J Bioequiv Availab. 2009;1:039-043.
10. Roda A, et al. Pharmacokinetics and Safety of a New 1200 mg Single-Dose Delayed Release Mesalazine Microgranule Formulation. J Bioequiv Availab. 2009;1:044-051.
11. Brunner M and Langer O. Microdialysis versus other techniques for the clinical assessment of in vivo tissue drug distribution. AAPS J. 2006;8:E263–E271.
12. Sudhakar A. The Matrix Reloaded:New Insight s from Type IV Collagen Derived Endogenous Angio-genesis Inhibitors and their Mechanism of Action. J Bioequiv Availab. 2009;1:052-062.
13. Flynn GL and Weiner ND. Dermal and Transdermal Drug Delivery, Drugs and The Pharmaceutical Sciences, Marcel Dekker, New York, 1989.
14. Riju A, et al. In Silico Screening Major Spice Phytochemicals for their Novel Biological Activity and Pharmacological Fitness. J Bioequiv Availab. 2009;1:063-073.
15. Song HH, et al. Pharmacokinetic Profiles of Two Branded Formulations of Piroxicam 20mg in Healthy Korean Volunteers by a Rapid Isocratic HPLC Method. J Bioequiv Availab. 2009;1:074-081.
16. Shirotake S, et al. Screening Bactericidal Action of Cytoplasm Extract from Kumazasa Bamboo (Sasa veitchii) Leaf against Antibiotics-Resistant Pathogens such as MRSA and VRE Strains. J Bioequiv Availab. 2009;1:088-085.
17. Gras PW, et al. Evaluation of a portable colour meter for assessment of the colour of milled rice. J Stored Prod Res. 1990;26:71–75.
18. Moreno RA, et al. Comparative bioavailability and pharmacodynamic aspects of cyclobenzaprine and caffeine in healthy subjects and the effect on drowsiness intensity. J Bioequiv Availab. 2009;1:086-092.
19. Groth L, et al. Microdialysis methodology for sampling in the skin. Handbook of Non-Invasive Methods and the Skin, In:Serup J, Jemec GBE, Grove GL (eds.) 2nd ed., CRC Press Taylor and Francis Group, Florida, USA 2006.
20. Lima R, et al. Bioequivalence of Final Tablet Formulation and Research Tablet Formulation of Eslicarbazepine Acetate in Healthy Volunteers. J Bioequiv Availab. 2009;1:093-098.

21. Yue PF, et al. Preparation, Characterization and Pharmacokinetics in Vivo of Oxymatrine–Phospholipid Complex. J Bioequiv Availab. 2009;1:099-102.
22. Hollander JL, et al. The use of intra-articular temperature measurement in the evaluation of anti-arthritic agents. J Clin Invest. 1950;29:822-823.
23. Moreira RF, et al. Effect of Hyperl ipemic Food on the Comparative Bioavailability of Two Bupropion Formulations after Administration of a Single Oral Dose of 150 mg in Healthy Human Volunteers. J Bioequiv Availab. 2009;1:103-111.
24. Najib NB, et al. Effect of Truncated AUC Method on Drug Bioequivalence in Humans. J Bioequiv Availab. 2009;1:112-114.
25. Lönnroth P and Strindberg L. Validation of the 'internal reference technique' for calibrating microdialysis catheters in situ. Acta Physiol Scand. 1995;153:375-380.
26. Teksin ZS, et al. Bioavailability of Pentoxifylline-Chitosan Oral Matrix Tablet in Healthy Subjects. J Bioequiv Availab. 2009;1:115-120.
27. Mahapatra L, et al. Pharmacokinetic Profile of Nimesulide in Bovine Calves. J Bioequiv Availab. 2009;1:121-026.
28. De Caro V, et al. Galantamine Delivery on Buccal Mucosa:Permeation Enhancement and Design of Matrix Tablets. J Bioequiv Availab. 2009;1:127-134.
29. Tettey-Amlalo RN and Kanfer I. Rapid UPLC-MS/MS method for the determination of ketoprofen in human dermal microdialysis samples. J Pharm Biomed Anal. 2009;50:580-586.
30. De Caro V, et al. Galantamine Delivery on Buccal Mucosa:Permeation Enhancement and Design of Matrix Tablets. J Bioequiv Availab. 2009;1:127-134.
31. Ayama T, et al. The Influence of Formula Concentration on the Absorption of Darbepoetin Alfa after Subcutaneous Administration. J Bioequiv Availab. 2010;2:001-005.
32. Lunestad BT, et al. The Effect of the Feed Oil and Protein Source on the Deposition and Depletion of Oxolinic Acid in Farmed Atlantic Salmon (Salmo Salar L.). J Bioequiv Availab. 2010;2:006-010.
33. Zhao Y, et al. Comparison of recovery and delivery in vitro for calibration of microdialysis probes. Anal Chim Acta. 1995;316:403-410.
34. Bapuji AT, et al. A Bioequivalence Study Comparing Two Formulation of Emtricitabine Capsules. J Bioequiv Availab. 2010;2:011-014.
35. Babu B, et al. Pharmacokinetic Evaluation of Metolazone Tablets using Healthy Human Volunteers. J Bioequiv Availab. 2010;2:015-017.
36. Frokjaer S and Otzen DE. Protein drug stability: a formulation challenge. Nat Rev Drug Discov. 2005;4:298-306.
37. Palma-Aguirre JA, et al. Bioavailability of Two Oral Tablet Formulations of citalopram 20 mg: Single-Dose, Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Adult Subjects. J Bioequiv Availab. 2010;2:018-022.
38. Lièvre A, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol. 2008;26:374-379.
39. Palma-Aguirre JA, et al. Bioavailability of Two Oral Tablet Formulations of citalopram 20 mg:Single-Dose, Open-Label, Randomized, Two-Period Crossover Comparison in Healthy Mexican Adult Subjects. J Bioequiv Availab. 2010;2:023-027.
40. Capriotti E, et al. I-Mutant2.0:predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2010;33:W306-310.
41. Krishnaiah YSR. Pharmaceutical Technologies for Enhancing Oral Bioavailability of Poorly Soluble Drugs. J Bioequiv Availab. 2010;2:028-036.
42. Loya P and Saraf MN. Determination of Amtolmetin and Its Active Metabolites in Plasma by HPLC-UV:Application to a Bioequivalence Study. J Bioequiv Availab. 2010;2:037-044.
43. Abib E, et al. Comparative Biological Availability of Clopidogrel Formulation in Healthy Volunteers After a Single Dose Administration. J Bioequiv Availab. 2010;2:045-049.
44. Sridhara R, et al. Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst. 2010;102:230-243.
45. Dewan B and Sahu N. Bioequivalence Study of Troxipide Tablet Formulations. J Bioequiv Availab. 2010;2:050-054.

46. Shakya R, et al. Comparative Bioavailability of Two Brands of Ofloxacin in Healthy Human Volunteers. J Bioequiv Availab. 2010;2:055-058.
47. Gong H, et al. Counting peptide-water hydrogen bonds in unfolded proteins. Protein Sci. 2011;20:417-427.
48. Olliaro P, et al. Pharmacokinetics and Comparative Bioavailability of Artesunate and Mefloquine Administered Separately or as a Fixed Combination Product to Healthy Volunteers and Patients with Uncomplicated Plasmodium Falciparum Malaria. J Bioequiv Availab. 2010;2:059-066.
49. Hussain S, et al. Assessment of Bioavailability of Rifampicin as a Component of Anti-tubercular Fixed Dose Combination Drugs Marketed in Pakistan. J Bioequiv Availab. 2010;2:067-071.
50. Gallo P, et al. Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group. J Biopharm Stat. 2006;16:275-283.
51. Alba E, et al. Anticipatory nausea and vomiting: prevalence and predictors in chemotherapy patients. Oncology. 1989;46:26-30.
52. Wang LH and Liu HJ. Determination of Fragrance Allergens in Essential Oils and Evaluation of their in vitro Permeation from Essential Oil Formulations through Cultured Skin. J Bioequiv Availab. 2010;2:072-076.
53. Khandave SS, et al. Evaluation of Performance of the Truncated Area Under Curve (AUC) as a Primary Pharmacokinetic Parameter in Bioequivalence Studies. J Bioequiv Availab. 2010;2:077- 080.
54. Chow SC and Chang M. Adaptive design methods in clinical trials - a review. Orphanet J Rare Dis. 2008;3:11.
55. Khandave SS, et al. Evaluation of Bioequivalence and Cardio-Hepatic Safety of a Single Dose of Fixed Dose Combination of Artemether and Lumefantrine. J Bioequiv Availab. 2010;2:081-085.
56. Tamboli AM, et al. An Overview on Bioequivalence:Regulatory Consideration for Generic Drug Products. J Bioequiv Availab. 2010;2:086-092.
57. Maca J, et al. Adaptive seamless phase II/III designs-background, operational aspects, and examples. Drug Inf J. 2006;4:463–473.
58. Selvadurai M, et al. Determination of Doxycycline in Human Plasma by Liquid Chromatography- Mass Spectrometry after Liquid-Liquid Extraction and its Application in Human Pharmacokinetics Studies. J Bioequiv Availab. 2010;2:093-097.
59. Bapuji AT, et al. Bioequivalence Testing - Industry Perspective. J Bioequiv Availab. 2010;2:098-101.
60. Kanfer I. Strategies for the Bioequivalence Assessment of Topical Dermatological Dosage Forms. J Bioequiv Availab. 2010;2:102-110.
61. Zakeri-Milani P, et al. Pharmacokinetic Study of Two Macrolide Antibiotic Oral Suspensions Using an Optimized Bioassay Procedure. J Bioequiv Availab. 2010;2:111-115.
62. López-Gamboa M, et al. Bioavailability of Long Acting Capsules of Melatonin in Mexican Healthy Volunteers. J Bioequiv Availab. 2010;2:116-119.
63. Sunkara G, et al. Assessment of Ethnic Differences in the Pharmacokinetics and Pharmacodynamics of Valsartan. J Bioequiv Availab. 2010;2:120-124.
64. Junior EA, et al. Bioequivalence of Two Oral Contraceptive Drugs Containing Ethinylestradiol and Gestodene in Healthy Female Volunteers. J Bioequiv Availab. 2010;2:125-130.
65. Zhang L, et al. Simulation Database System of the Active Ingredients in Compound Decoction of Chinese Medicine. J Bioequiv Availab. 2010;2:131-134.
66. Shafaati A, et al. Rapid and Sensitive Determination Of Montelukast in Human Plasma by High Performance Liquid Chromatographic Method Using Monolithic Column:Application to Pharmacokinetic Studies. J Bioequiv Availab. 2010;2:135-138.
67. Khattak S, et al. Comparative Bioavailability Assessment of Newly Developed Flurbiprofen Matrix Tablets and Froben SR® Tablets in Healthy Pakistani Volunteers. J Bioequiv Availab. 2010;2:139-144.
68. Abu-Basha EAH, et al. Pharmacokinetics and Bioequivalence of Florfenicol Oral Solution Formulations (Flonicol® and Veterin®10%) in Broiler Chickens. J Bioequiv Availab. 2012;4:001-005.
69. Zou JJ, et al. Bioequivalence Study of Clopidogrel 75 mg Tablets in Healthy Male Volunteers. J Bioequiv Availab. 2012;4:006-009.
70. Awad AM. Application of Information Theory to Bio-Equivalence Problem. J Bioequiv Availab. 2012;4:010-013.
71. César IC, et al. Bioequivalence Study of Two Oral Formulations of Memantine Tablets in Healthy Brazilian Volunteers after a Single Dose Administration. J Bioequiv Availab. 2012;4:014-017.
72. Nichols AI, et al. The Absolute Bioavailability of Desvenlafaxine in Healthy Subjects. J Bioequiv Availab. 2012; 4:018-023.

73. Nichols AI, et al. Effect of Food on the Pharmacokinetics of Desvenlafaxine in Healthy Subjects. J Bioequiv Availab. 2012;4:024-029.
74. Ruiz A, et al. Bioequivalence Evaluation of Two Formulations of Lamotrigine Tablets in Healthy Volunteers. J Bioequiv Availab. 2012;4:030-034.
75. Hernandez E, et al. Bioavailability of Two Different Coated-Tablet Formulations of Valacyclovir of Two Different Strengths (500 mg and 1000 mg) in Healthy Mexican Adult Volunteers. J Bioequiv Availab. 2012;4:035-039.
76. Harahap Y, et al. A Bioequivalence Study of Two Azithromycin Tablet Formulations in Indonesian Healthy Subjects. J Bioequiv Availab. 2012;4:048-051.
77. Mavrova AT, et al. Cytotoxic Effects of Some N-Substituted-2-Amino-1H-Benzimidazoles. J Bioequiv Availab. 2012;4:052-055.
78. Abib E Jr, et al. Comparative Bioavailability:Two Pramipexole Formulations in Healthy Volunteers after a Single Dose Administration under Fasting Conditions. J Bioequiv Availab. 2012;4:056-059.
79. Ayrapetyan S, et al. Age-Dependent Brain Tissue Hydration, Ca Exchange and their Dose-Dependent Ouabain Sensitivity. J Bioequiv Availab. 2012;4:060-068.
80. Wang M, et al. Decreased Subcutaneous Bioavailability of an Oxyntomodulin Analog in a Controlled Release Formulation could be Caused by Skin Metabolism in Rats. J Bioequiv Availab. 2012;4:069-077.
81. To C, et al. Comparison of Components and Anti-Liver Cancer Activity In vitro between Huanglian and Yunlian. J Bioequiv Availab. 2012;4:086-090.
82. Akarasereenont P, et al. Bioequivalence Study of 1,500 mg Glucosamine Sulfate in Thai Healthy Volunteers. J Bioequiv Availab. 2012;4:091-095.
83. Zhao J, et al. Hemolysis of Blood Samples has no Significant Impact on the Results of Pharmacokinetic Data. J Bioequiv Availab. 2012;4:082-085.
84. Bartoli AN, et al. Bioavailability of a New Oral Spray Melatonin Emulsion Compared with a Standard Oral Formulation in Healthy Volunteers. J Bioequiv Availab. 2012;4:096-099.
85. Mathias A, et al. Bioequivalence of the Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Single Tablet Regimen. J Bioequiv Availab. 2012;4:100-105.
86. Chen Y, et al. Urinary Study on the Biochemical Effect of Acupuncture on Monosodium Urate Crystals-Induced Acute Gouty Arthritis in Rats using 600MHz 1H NMR. J Bioequiv Availab. 2012;4:106-111.
87. Ayrapetyan S, et al. Na/K Pump α3-Isoform-Dependent Cell Hydration Controlling Signaling System Dysfunction as A Primary Mechanism for Carcinogenesis. J Bioequiv Availab. 2012;4:112-120.
88. Babu B, et al. Pharmacokinetic Evaluation of Newly Developed Oral Immediate Release and Sustained Release Dosage Forms of Losartan Potassium. J Bioequiv Availab. 2012;4:121-127.
89. Madhavi N, Sudhakar B, Ravikanth PV, Mohon K, Ramana Murthy K (2012) Formulation and Evaluation of Phenytoin Sodium Sustained Release Matrix Tablet. J Bioequiv Availab. 4:128-133.
90. Semdé R, et al. Evaluation of the Bioequivalence Documentation Required For Registration of Generic Drug Products in Burkina Faso: Methodology of Implementation and Impact. J Bioequiv Availab. 2012;4:134-138.